Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 22

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 22
---
 programs in light of such votes;

establishing policies with respect to equity compensation arrangements;

reviewing and assessing the elements of our compensation program as they relate to enterprise risk and the management of any such risks;

assessing the independence of each compensation consultant, legal counsel and other advisor to the Human Capital Committee, in accordance with and to the extent required by applicable law and Nasdaq;

reviewing with management any required disclosures under the caption “Compensation Discussion and Analysis” and recommending to the Board its inclusion in our periodic reports to be filed with the SEC;

<div align='center'>12</div>

develop, implement, and periodically review with management, our Incentive Compensation Recoupment Policy (“Clawback Policy”) and Stock Ownership Guidelines for the Company’s directors and executive officers, and monitor compliance with such guidelines;

periodically review with the Chief Executive Officer the plans for succession for the Company’s executive officers;

reviewing and designing policies and strategies relating to talent management and development, talent acquisition, culture, and employee engagement;

preparing the report on executive compensation to be included in the Company’s annual proxy statement;

reviewing and recommending to the Board the annual corporate goals of the Company for approval by the Board and assessing the achievement of the Company’s such corporate goals annually and report to the Board on such assessment, for approval by the Board;

reviewing and discussing with management the Company policies and training and developing programs designed to support the long-term goals of the Company, including but not limited to goals relating to employee health, safety and well-being; environmental, social, and governance; and diversity and inclusion; and

reviewing and evaluating, at least annually, the performance of the Human Capital Committee and the adequacy of its charter.

The Human Capital Committee has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has adopted a written Human Capital Committee charter that is available to stockholders on our website at http://investors.atarabio.com/governance.

Human Capital Committee Processes and Procedures

The Human Capital Committee met five times during 2024. The agenda for each meeting is usually developed by our Chief Executive Officer, VP, Chief People Officer, Chief Financial Officer, and Chief Legal Officer in consultation with the Chair of the Human Capital Committee and our outside compensation consultants, if applicable. The Human Capital Committee meets regularly in executive session. However, from time to time, various members of management and other employees, as well as outside advisors or consultants, may be